253 results about "Anti inflammatories" patented technology

The invention discloses an anti-inflammation active component group of a stomatitis clearing preparation and an analysis method. Fingerprint characteristic spectra of the component group are constructed and are applied to detecting the quality of the stomatitis clearing preparation. The analysis method which is a quality detecting method particularly includes detecting the quality of the stomatitis clearing preparation by the aid of a detection index which is anti-inflammation efficacy; uniformly designing difference samples with different component proportions; acquiring fingerprint characteristic data of the difference samples by the aid of UFLC-Q-TOF-MS/MS (ultrafast liquid chromatography-quadrupole-time of flight-mass spectrometry/mass spectrometry) technologies; acquiring anti-inflammation activity data of the preparation. The relevance between chemical components of the difference samples and the efficacy is comprehensively analyzed by the aid of the mathematical statistics method, accordingly, 29 anti-inflammation efficacy active components can be determined, and the fingerprint characteristic spectra of the component group can be constructed. Compared with the prior art, the anti-inflammation active component group and the analysis method have the advantages that the active component group is analyzed on the basis of the relevance between the spectra and the efficacy, accordingly, the quality of raw medicinal materials, semi-finished products and finished products can be directly, objectively, scientifically and comprehensively monitored in production procedures, and the effectiveness and the quality consistency of the products can be guaranteed.

The present invention provides an excellent drug delivery system to posterior segments. An injection according to the present invention is a periocular injection which comprises fine particles containing a drug and enables the drug to deliver to the posterior segments. The drug can be efficiently delivered to the posterior segments (such as a retina, a choroid and an optic nerve) while scarcely injuring ophthalmic tissues by administering the fine particles containing the drug periocularlly. Preferred fine particles are made of a synthetic biodegradable polymer, their average particle diameter is 50 nm to 150 μm, and the drug is dispersed in the fine particles uniformly. Preferred drugs are anti-inflammatories, immunosuppressors, antivirals, anticancer drugs, angiogenesis inhibitors, optic neural protectants, antimicrovials and antifungal agents.

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

A composition comprises plasmin or an enzymatically equivalent derivative thereof and at least an anti-inflammatory medicament. The composition can be used to effect or induce a controlled posterior vitreous detachment (“PVD”) to prevent, treat, or ameliorate a potential complication of a pathological ocular condition. Such a composition can be administered intravitreally.

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.

The invention discloses a diterpenoid compound and the preparing method and application thereof. The diterpenoid compound is obtained by using aralia melanocarpa roots as the raw material through extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation. The molecular formula of the diterpenoid compound is C20H30O3. The name of the diterpenoid compound is 14-oxygen-ent-8(9),15-(14-oxo-ent-pimara-8(9),15-diene-19-oic acid). The structural formula is as shown in the specification. According to the preparing method, aralia melanocarpa roots are used as the raw material, and extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation are conducted to generate the diterpenoid compound. The diterpenoid compound can be applied to preparation of anti-inflammatory drugs for prevention and/or treatment. The diterpenoid compound is subjected to in-vitro anti-inflammatory activity testing, and experimental results show a good lipopolysaccharide (LPS) restraining effect and a good effect of inducting pulmonary alveolar macrophages (RAW264.7) to generate NO. A new compound or lead compound with high application value can be provided for the medical industry.

The invention belongs to the technical field of medicines and discloses new diarylheptanoid compounds extracted and separated from Guangxi curcuma zedoary and application thereof in the field of medicines. The chemical structure of the diarylheptanoid compounds is determined by spectrum technology such as a high resolution mass spectrum, one-dimensional and two-dimensional nuclear magnetic resonance spectrum and the like, and a chemical method. The diarylheptanoid compounds can be combined with a pharmaceutically acceptable carrier to prepare clinically acceptable medicines for anti-inflammatory treatment. Experiments for inhibiting lipopolysaccharide-induced rat macrophage from synthesizing nitric oxide (NO) in vitro prove that: the diarylheptanoid compounds have high activity of inhibiting the nitric oxide from being generated, and can be used as anti-inflammatory medicines for preventing and/or treating human and animals.

Methods and apparatus of providing a subject with post-operative, sustained-release of a biological agent within a synovial joint is disclosed. These methods involve securing a depot containing the biological agent to a ligament, tendon, muscle within the joint to provide sustained-release of the agent while allowing for normal joint articulation. This methodology may be utilized to provide for sustained-release of a biological agent useful in treating various traumas and disorders of the joint. Such biological agents include antagonists of inflammation-related proteins, such as TNF-α, IL-1β, IL-6, IL-8, NF-κB, High Mobility Group Box 1 (HMG-B1), IL-2, IL-15 and steroidal and non-steroidal anti-inflammatories. Other biological agents include anti-inflammatory cytokines such as IL-10, IL-4, IL-13, and TGF-β. The biological agents also include osteogenic and cartilage producing growth factors such as, but not limited to, BMP-2, BMP-4, BMP-6, BMP-7, BMP-8, and MIA CD-RAP. Finally, the biological agents include siRNA and/or therapeutic antibodies.

The invention relates to a drug-loaded mesoporous-silica-reinforced dental binder and a preparation method thereof. The binder comprises following components by weight: 40-60% of a resin component, 35-50% of a dilution component, 2-10% of an acid monomer, 0.2-0.5% of a photoinitiator, 0.1-0.3% of a promoter, a trace amount of a polymerization inhibitor and 1-10% of mesoporous silica. The binder has high strength and drug releasing property, and therefore the binder is advantaged by loading and performing controlled releasing of antibacterial agents, anti-inflammatory drugs, hemostatics, etc.. The binder not only has a binding function, but also has certain functions of treating and preventing bacterial infection, and can be used as a dentine binder in clinic.

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

The invention relates to an alginate-drug loaded nanoparticle-polycation microcapsule and preparation and application thereof. The microcapsule product is a spherical microcapsule with a particle sizeof 100 to 1000 microns. The structure of the microcapsule product is divided into two parts of a microcapsule membrane and an inner core. The microcapsule membrane is self-assembled layer by layer byalginate, drug-loaded nanoparticles and polycations to form a polyelectrolyte composite hydrogel film, and the inner core is a hydrogel or hydrosol environment containing animal cells. The microcapsule product is used as an immunosuppressive tool in embedding carriers for cell transplantation. Under the premise of ensuring the microcapsule strength and immuno-isolation performances, the surface roughness and surface charge of the microcapsule membrane can be reduced, the in-situ release of an anti-inflammatory drug on the surface of the microcapsule is realized, and the problem of fibrillation wrapping is solved from two aspects of stabilization of the microcapsule membrane by the drug-loaded nanoparticles and in-situ release of the anti-inflammatory drug for anti-inflammation.

The invention discloses a method for treating malignant tumors with joint medicament administration and also discloses an anti-malignant tumor medicinal composition with an antitumor activity and a low toxicity and an anti-malignant tumor medicinal preparation using the medicinal composition as an active component. The method comprises a step of jointing administrating anti-inflammatory medicaments, such as glucocorticosteroids or immunosuppressive agents or biotic agents of target cell factors and a carboxamidotriazole or derivatives or intermediates of the carboxamidotriazole as a medicamentto treat malignant tumors, wherein the anti-inflammatory medicaments have a certain regulation effect on cell factors. Tests prove that the combined medicament can increase the sensitivity of tumor cells to the carboxamidotriazole, so the combined medicament can be used as a broad-spectrum medicament for treating a plurality of malignant tumors, particularly non-small cell lung cancer, colon cancer and the like.

Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions.

Aspirin and phenol antioxidant p-hydroxyphenyl acrylic acid or ferulic acid are used as materials to prepare two kinds of antioxidant aspirin derivatives, named separately as 2-acetoxy-benzoic acid-2-[3-(4-acetoxy-phenyl)-acrylyloxy]-acetate and 2-acetoxy-benzoic acid-2-[3-(3-methoxy-4-acetoxy -phenyl)-acrylyloxy]-acetate chemically. The antioxidant aspirin derivatives are used in preparing antiphlogistic medicine.

The invention relates to ten 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidinone compounds having anti-tumor and anti-inflammatory activities, and belongs to the technical field of anti-tumor and anti-inflammatory medicines. A preparation method of the 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidinone compounds comprises the following steps: firstly, performing claisen-schmidt condensition reaction on 4-piperidinone hydrochloride and aromatic aldehyde to obtain a 3,5-bis(arylidene)-N-H-4-piperidinone hydrochloride intermediate product so as to further perform benzene sulfonylation on the 3,5-bis(arylidene)-N-H-4-piperidinone hydrochloride intermediate product and a sulfonylation reagent to obtain the 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidinone compounds. The compounds have good anti-tumor and anti-inflammatory activities, can avoid the genetic toxicity of currently-used anti-tumor medicines, have little toxicity to normal cells, and also have good anti-inflammatory activity.The preparation method is simple and convenient to operate, is mild in reaction conditions, is high in synthetic yield, and is beneficial for being widely popularized in anti-tumor and anti-inflammatory fields.

The invention belongs to the field of the pharmaceutical chemistry and pharmacology, and concretely relates to an application of a compound of [(1E,1'E)-(4-Oxo-1-propionylpiperidine-3,5-diylidene)bis(methanylylidene)]bis(2-methoxy-4,1-phenylene)dipropionate (S1) in the preparation of anti-inflammation or/and anti-oxidation drugs. The above piperidone type curcumin analog S1 can dose-dependently inhibit the expression and release of inflammation factors comprising TNF-alpha, IL-6 and the like, and can also obviously improve the survival rate of mice death-induced by LPS. The compound has a good safety and stability, and can be exploited to inflammation or/and oxidation stress related disease treatment drugs.

The invention discloses a preparation method for a polylactic acid nanofiber scaffold functionally modified by two-dimensional nanometer black phosphorus, and aim to provide a preparation method for amultifunctional modified polylactic acid scaffold. The preparation method is characterized in that a black phosphorus nanosheet is taken as a medicine carrier to load an anti-inflammatory medicine, i.e., ibuprofen, a natural high polymer material, i.e., sodium alginate, is taken as a coating material, and through a crosslinking function of strontium ions, a medicine-carrying microsphere is obtained; an electrostatic interaction is used for evenly doping a sodium alginate medicine-carrying microsphere into a modified polylactic acid basis material which is subjected to ammonolysis and modification by branched polyethyleneimine and is rich in an active amino group; and through freezing phase separation, the modified polylactic acid scaffold with a reticular nanometer fiber structure is obtained. The preparation method has the characteristics that the prepared modified polylactic acid nanofiber scaffold embedded with the medicine-carrying microsphere is a multifunctional system with thefunctions of performing photothermal therapy, accelerating bone growth, resisting bacteria, diminishing inflammation and intelligently releasing medicines, and the polylactic acid nanofiber scaffold is an ideal bone repairing material.

The invention relates to a flavonoid glycoside compound in flos elaeagni angustifoliae, and a preparation method thereof. The method comprises the following steps: taking flos elaeagni angustifoliae medicines as raw materials, extracting by solvent, extracting by solvent, carrying out separation through two or three ways including positive phase and reverse phase silica gel column chromatography,or glucan gel LH-20 column chromatography and a semi-preparation high-performance liquid chromatography, adopting thin-layer chromatography and the high-performance liquid chromatography to detect andanalyze to obtain two new flavonoid glycoside compounds, wherein the first compound is flos elaeagni angustifoliae glycoside A, and the second compound is flos elaeagni angustifoliae glycoside B. Through the measurement of in vitro inhibition of COX (cyclo-oxygense) enzyme activity, an experiment result indicates that the flavonoid glycoside compound separated from the flos elaeagni angustifoliaecan inhibits the COX enzyme activity in different degrees, and the flavonoid glycoside compound in flos elaeagni angustifoliae can be used for preparing anti-inflammatory medicines.